We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with 9 of the world’s top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
Continuous innovation is the lifeblood of our business. Therefore, we undertake dedicated R&D in areas that have significant growth potential. We filed 238 patents in which we own 81 patents. We have commercialised 50+ products since inception across four distinct business units: Generics API, Generics FDF, Ingredients and Synthesis.
As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.